This edition of the epistles of Doc Gumshoe won’t be entirely about Alzheimer’s, but there are Alzheimer’s-related news items that jump to the top, based on timeliness, if nothing more. When Doc Gumshoe last wrote about what was happening on the Alzheimer’s front, a big chunk of the piece was the FDA’s surprising – and […]
Articles
Ed. Note: This article was originally posted on June 15, 2021. It is being re-run here because we’re getting questions as this is touted as a “brand new buy alert” in recent ads, the ads themselves have not changed and this particular article has not been updated since publication. FYI: The stock teased, DNLI, is […]
I was hoping to keep COVID-19 out of this piece, but new things keep flooding in, and I can’t totally ignore them. However, I’ll save them to the end of the story. They are both “good news,” more or less, and I like to leave you with a bit of cheer, when possible. Sleep and […]
Which means, the more things change, the more they stay the same. The big change in the Alzheimer’s disease world – which you’ve all heard about, no doubt – is that the FDA granted emergency use authorization to aducanumab, now to be named Aduhelm. That happened on the 6th of June. The FDA’s decision elicited […]
Before I launch into the topics of the day, I am going to share with you an opinion piece about the recent CDC guidelines. I find myself in complete concurrence with this piece, which was posted a few weeks ago on MedPage Today, a medical website that is a very helpful source of information for […]
Many of the comments to these Doc Gumshoe pieces go like this: “What do you know about such-and-such a drug, or about what this or that person (usually a physician) has to say about cancer, or heart disease, or (especially these days) about COVID-19?” My right-off-the-bat response to most of these would usually be “not […]
If the answer to those two questions should turn out to be an unequivocal “Yes!” that would definitely be cause for champagne and fireworks. Sorry to say that for now, at least, we have to put the champagne and fireworks on hold. But, who knows, might there be something – a few snippets […]
I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
The last time I wrote about Parkinson’s I had not yet become Doc Gumshoe. It was quite a few years ago, and I was working on a continuing medical education project in support of donepezil (Aricept, from Eisai/Pfizer). Aricept, as you may know, is one of a very few drugs approved for the […]
Having just devoted an entire Doc Gumshoe piece to the notorious coronavirus (COVID 19), I’m going to make those coronavirus updates brief – it looks to me as though the news media is devoting a major part of its capacity to covering most aspects of this pandemic – and, yes, it now certainly looks like […]
Today we’ve got a teaser pitch from Dylan Jovine’s new service, Takeover Targets, which he says is “half price” for charter subscribers (that would be $997/year, and unlike many higher-end newsletters they say they do offer refunds for 30 days)… and, as you might imagine, the service is all about identifying companies that might be […]
The many welcome comments to the Alzheimer’s piece that posted a couple of weeks ago prompt me to supply answers (if I am able to do that), but also set my mind to wandering on the fringes of a number of issues that may be of interest to the Gumshoe constituency. Anavex 2-73 At the […]
From where I sit, it seems to me that the entire landscape of Alzheimer’s disease (AD) has changed, and changed quite significantly. The litany of announcements from pharmaceutical companies big and small revealing the unfortunate news that yet another promising agent for the treatment of AD has failed to meet its objectives in a […]
One would think that it would take a person of normal intelligence about half a minute to conclude that lures such as the ones below could not possibly be on the up and up. Here’s one. It starts out with a note from Christine O’Brien. “The Sovereign Investor Daily A brand new, ‘Alzheimer’s vaccine’ […]
I have no idea what’s going to happen in the market today, but perhaps if I spend my time looking into a teaser pitch from a new newsletter I’ll be too busy to obsess over my portfolio and do something dumb during the trade war panic gyrations. Sound good? Want to join me? Great! The […]
Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]
I’ll grant that my headline is meant to be catchy and induce you to read this epistle. Some of you will ask what is ketamine anyway, and most of you will know from the get-go that ketamine, whatever the heck it is, will turn out to be neither a menace nor a miracle, but something […]
Ray Blanco makes (part of) his living looking for biotech moonshots, like most biotech-focused newsletter writers — and like his predecessor at Agora’s biotech and emerging tech-focused newsletter Breakthrough Technology Alert, he has often touted companies that are trying to end the scourge of Alzheimer’s Disease. Why? Well, two main reasons: First, and by far […]
Is this going to be good news, or bad news, or somewhere in between? On balance, I would say good news, simply because the research and investigation is going on at an intense pace. Currently there are 1,903 clinical trials underway at some stage, in the US and all over the world. When I first […]
This is a bonus weekend “quickie” for you, so it’s not a stock I’m going to go in depth on… but I thought you might want a few moments to think about it while the market’s not open. The promise is absurd, here’s a taste of it from the top of the ad: “ALERT: Agora […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he […]
We are always, always tempted by anything that promises hope to sufferers of Alzheimer’s Disease and their families… not just because we’re humanitarians and love people, and have seen the pain of this disease, but because Alzheimer’s treatment is by far the largest (mostly) unmet medical need in the US, both because the population of […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
Alzheimer’s Disease always gets a lot of attention from newsletter publishers, readers and investors — not only because we all know someone who suffers from this terrible malady, but because we know that the current treatments are ineffective and the market is huge… which means that any real solutions or more effective treatments could create […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All of his past […]
Alzheimer’s Wrap-Up[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” writes about health and medicine for us from time to time. His columns are not generally focused on investments, though this one does include some commentary about a number of specific companies (most are not publicly traded). His words and opinions are his own, […]
[ed. note: Michael Jorrin is a longtime medical writer who writes about health and medicine a couple times a month for our readers, usually without a specific investment focus — though it so happens that today’s topic, Alzheimer’s, is also subject to at least one current heavily-hyped investment pitch. I like to call him “Doc […]
10/28 update: this article is about a week old, but the teaser ads have changed a bit — the newsletter is now also being pitched under the headline, “Has this Maine town bottled the fountain of youth?” and it’s now also going out under the name Dr. Richard Robinson, who apparently works on the newsletter […]
[ed note: Michael Jorrin, who we like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who writes non-investment articles about medicine and health topics for us once or twice a month. As with all of our guest contributors and columnists, he chooses his own topics and his words are his alone] […]
That’s a subtle headline, right? I already issued a bit of a “brain dump” for the Irregulars this week, on Wednesday instead of Friday, but I couldn’t resist taking a little look at this latest teaser pitch from Patrick Cox for his Transformational Technology Alert. Quite a few readers have been asking about it, and […]
[ed note: Michael Jorrin, aka “Doc Gumshoe,” is a medical writer (not a doctor) who shares his thoughts with us once or twice a month. As with all our guest authors, his words and opinions are his own] The stream – or should I say “torrent” – of medical and health-care related news doesn’t seem […]
[ed note: This is another installment from our favorite medical writer, Doc Gumshoe (no, he’s not a doctor, but we like the way he analyzes and explains medical issues for our readers). Since he’s talking about specific companies this time, we’ve restricted the piece to the Irregulars and have inserted some comments about the stocks […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
I always feel a swell of optimism when I read a teaser ad from Patrick Cox — something about his relentless happy-facing about the teensy tiny technology and biotech companies he loves just stirs me up a little bit, reminds me that the reason many of us dabble in microcap stocks, little mining companies, new […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
What about the age suppresor gene Klotho and Alzheimers? UCSF is working with this. This is a gene which was discovered ...
Just wanted to see if you have any information on SAVA. Cassava sciences. Apparently they have an AZ drug in phase 3 tri...
Alzheimer's: The heretical and hopeful role of infection Is Alzheimer's triggered by infection? 6th October 2021 What...
The issue with Alzheimer's Disease (AD) drug treatment hopefuls doesn't have much to do with whether or not someone has ...
Michael. Thanks for this article. Would it be possible for you to take a look at the unique approach that SAVA has tak...
The next big thing in Alzheimer's research, not a drug, a process .... Halberd Corporation Alzheimer's Disease Treatmen...
THANK YOU SO MUCH FOR POSTING THIS INFORMATION. I printed it and will be discussing it with the research doctor today a...
Michael, We were told by the research doctor that my husband may not qualify for the phase 3 study simply because he did...
I MADE A FEW ERRORS!OPPS in 2013 Dr Miklossy published a study calling Alzheimer’s a neurospirochetosis. Open Access ...
in 2013 Dr Miklossy published a study calling Alzheimer's a neurospirochetosis. Open Access Alzheimer’s disease - a n...
My husband is on his final week of FASUDIL. He has done GREAT. Unfortunately it is JUST a Phase 2 study and it needs t...
I read a study by a European researcher a few years ago that stated alzheimers disease was caused by the overoccupation ...
Travis: Thank you for the venture funding update and some background on Denali Therapeutics and their scientific resear...
this is about you taking a shot a trump because of the who investigating the covid im sure they are a great org and h...
This is amazing results for both AD and PD. Small peek at the phase 2. ony 14 patients each - but huge results. Blow awa...
My husband is in a new study that is showing promise for us in regards to Alzheimer's. When he was on the "open label"...
Own AVXL and SAVA. Purchased both because of the possibility to help my family battle Alzheimer's disease. Believe that ...
Promis Neuroscience is worth looking at - otc is “arfxf “- red about their PMN310 - I think partnered with a larger ...
In the end, what has happened to the effect on the Alzheimer's disease by this Promind Complex? Was it not the purpose o...
Are the results of the UCLA study for the bioavailable curcumin product better than those for Alzheimer's drugs?...
I would take into consideration this comment in the Washington Post for Simonian who also writes articles for SA: The...
ACW.asx Actinogen presents latest Xanamem data at AD Conference https://actinogen.com.au/asx-announcements/ Above is l...
Wouldn’t be surprised if he likes that one, the reward potential of Alzheimer’s Disease drugs always tempts newslett...
Doc, I found this comment very interesting: "Memantine (Namenda), from Forest Pharmaceuticals, an antagonist of N-methy...
Micheal - Thank-you for your follow-up but I feel you have shortchanged us again on Anavex. They have a placebo controll...
Good Morning ! I have been watching ANAVEX for several years now. They have a promising drug that utilizes precision g...
$INND Innerscope Hearing Technologies, Inc. Good to hear from you Wfuiii. I've nibbled again. There will be further...
$INND Innerscope Hearing Technologies, Inc. https://www.innd.com/ MarkeTrak 10: Hearing Aids in an Era of Disruption ...
https://assets.boardroom.media/company_logo/ccdd47bd-38a1-4648-a771-398f23d727eb.jpg $ACW.asx Actinogen Medical > ...
Thank you Michael for this refresher, update and all your very informative articles. Announced this article on Twitter...
The two leading world experts on Alzheimers are Dr Dale Bredesden who has written a book entitled 'The End of Alzheimers...
This was immensely interesting as my mother has Alzheimer’s. You do not mention anywhere the research carried out by D...
Prevention is much more effective that treatment. Other measures include exercise, eating little or no sugar and doing m...
Four years ago, we returned to our retirement home, purchased over 40 years previously. Going to greet our neighbors, w...
Comprehensive Michael, thanks. In Aus, we got this new two days ago, (Stock went up 450%) but here is a little of what t...
Please look at Anavex Life Sciences: AVXL as I believe that they are on the right track with their A2-73 drug candidate ...
Thank you very much for the interesting article on Alzheimer's Disease. A family member has this condition and you are c...
You might want to have a look at AVXL. From today's MT Newswires: "07:42 AM EDT, 10/02/2019 (MT Newswires) -- Anavex Li...
If you want to lower your blood sugar, a simple Ketogenic diet will do the trick. Preliminary studies show it works to i...
Virtual reality can spot navigation problems in early Alzheimer's disease by University of Cambridge https://medicalxpr...
Fred, sorry I missed your comment on L-serine. Have you found another source that taste's ok/better? I have not found...
Another failure in Alzheimer's Disease trials... BIIB and Eisai discontinued their late Phase 3 trials because they were...
This is a business there will he sales nonsense and I looked before I bought in bought in about their opt out policy. Th...
What is Ray Blonco's "Alzheimer’s Disease cure" 4olbear....
Anybody with experience using L-serine for preventative for ALS Alzheimers?; I can not find on retail market. I read an...
There may be something behind this. A 2017 book "The End of Alzheimer's..." published by Penguin/Random House, written b...
#86AD > Mandelblatt cautioned that her study was still too small to reach any conclusion, but if future studies could re...
I hope it works well for you, and that their drug is both effective and profitable. I've gotten very skeptical about Al...
Hello Doc, All, I have hesitated to mention this company involved in this field, but since we are on a common thread, na...
Many interesting comments in response to that Alzheimer’s piece. I’ll try to respond to as many as I can. And ma...
Hi Doc. What do you think about ANAVEX ? They are starting a phase 3 and here are the recent bullets. One huge positive ...
What does running do to your #brain? https://pbs.twimg.com/media/DhHfG2ZWAAYz_xC.jpg ty https://twitter.com/LEAD_C...
New development in 3-D super-resolution imaging gives insight on Alzheimer's disease https://phys.org/news/2018-07-d-su...
$AXSM > Bid 204K at $3.05 Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer's Association Interna...
Yet More Evidence that Viruses May Cause Alzheimer's Disease https://gizmodo.com/yet-more-evidence-that-viruses-may-cau...
Excitement about Alzheimer's drugs sometimes spurs big movements in Phase 1 and 2, though so far almost all of them have...
I'm trying to assess the opportunity for an investment in Promis Neurosciences. They are a pre-clinical stage biotech co...
$VTVT np - vTv Therapeutics Inc. has added a news release to its Investor Relations website. Title: vTv Therapeutics ...
$VTVT np - vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in Pe...
See research at Paul H. Duray Pathology Research Fellowship that show borrelia burgdorferi aka Lyme disease spirochetes ...
Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease https://www.nature.com/articles/s415...
$ORY.BME - Oryzon to present at upcoming international conferences Madrid, Spain and Cambridge, MA - February 21st 20...
#AD - Arthritis drugs could halve the risk of Alzheimer's disease, study suggests http://www.telegraph.co.uk/news/2018/...
#AD - PMN.to NP - As someone who lost their father to alzheimer's disease, I did a fair bit of research into this compan...
$CWBR #MDPs New research article published in the journal of Alzheimer’s and Dementia supports a mitochondria(MDP)-b...
#AD #Tunes Another joy to parents/patients with Alzheimer's Disease is playing/listening to their favorite #music. Some...
Yep, there is a very wide gulf separating "Alzheimer’s Disease is Now Completely Treatable”" and "could give hope to...
#Alzheimer's Disease $CWBR Article: Dementia Shown Associated with Synaptic Dysfunction Rather Than Synaptic Loss GEN N...
Question of the week Maybe a bit of a trick question? My quick research says that the answer is HDV. It also says t...
NTRP-NP. Looking for $6.55 ( untested low) for SP. I am surprised that there hasn't been more interest in this outfit. R...
$AXSM UW Axsome announces recommendations to continue COAST-1, discontinue CREATE-1 trial Axsome Therapeutics an...
#Alzheimers Disease $Biogen$Merck$J&J$Denali Nice summary article in WSJ "Drug Industry Isn't Giving Up On Alzheimer's" ...
TRAVIS, LYNN, #ZKSS one in Moderation replaced by this one... #Alzheimer's #Disease #AD… The Neuroscience Inno...
$NTRP np - https://www.morningstar.com/news/pr-news-wire/PRNews_20171219NY73157/neurotrope-to-present-additional-findin...
$NTRP (long) [Post-hoc subgroup analysis of Phase 2 patients, completed May 2016, shows that Bryostatin had an appare...
$PFE Pfizer Ends Hunt for Drugs to Treat Alzheimer’s and Parkinson’s - About 300 layoffs to take place after once...
$Alzheimer Hi John, scary indeed. Last I heard the role of tau-phosphorylation in the pathogenesis of Alzheimers Dis...
$Alzheimers $AD (A great read of new research findings) Alzheimer’s protein may spread like an infection, human...
#Alzheimer'sDisease - Healthy mitochondria could stop Alzheimer's Date: December 6, 2017 Source: Ecole Polytechnique F...
#Alzheimer's Disease related - How Loneliness Affects Our Health https://www.nytimes.com/2017/12/11/well/mind/how-lonel...
Grief is convoluted but does have two "messy" phases: LOSS -as you plunge into a pit of pain and confusion, and then, ...
#Alzheimer's Disease related - http://fortune.com/2017/12/01/human-longevity-dna-ceo-out/...
#Alzheimer’s Disease Protective Alzheimer’s Gene Variant Uncovered ---> Linkage, whole genome sequence, and biologi...
#Alzheimer's Disease Protective Alzheimer's Gene Variant Uncovered https://genomemedicine.biomedcentral.com/articles/10....
Michael Jorrin - This was posted on the ihub message board this morning. This is too lengthy for your comment section bu...
My research into Alzheimer’s potential “cures” or drugs that do not attack the disease from the amyloid plaque ang...
What do you think about "Anavex Life Sciences Says Study of ANAVEX2-73 Shows Improvement in Alzheimer's Disease Patients...
Are you aware of the work by Dr Dale Bredesen? Here is a summary of that work as reported by Dr Mercola on his website:...
$ AXSM NP : (AXSM) More News 08-Nov-2017:07:00:00, Axsome Therapeutics Reports Third Quarter 2017 Financial R...
$Anti-aging $Mitochondria (?) An exciting new research report from NATURE (11/1) “Infusions of young blood tes...
$AXON np #FAIL Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease http:/...
$AXON -- I wish I had the guts to short this. Interesting piece on Alzheimers but doc is embargoed 'til December. Long-...
#Alzheimer's_Disease - $BIIB - Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Trea...
#Alzheimers _Hypothesis “Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer’s Disease.” St...
#Alzheimers _Hypothesis “Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer’s Disease.” St...
$Alzheimers $Hypothesis "Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer's Disease." Sternb...
I wrote today about a different Alzheimer's Disease drug being tested in mice, not the one Doc Gumshoe mentioned. It als...
$AXSM long - Prognosticating report and update tomorrow, Aug 9th, as that was the date last year. http://finviz.com/qu...
Molecular link between post-traumatic stress disorder and Alzheimer's disease https://medicalxpress.com/news/2017-08-m...